Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy | MicrobiomeTrials
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
CompletedPHASE2INTERVENTIONAL
Trial Details
Start: 2021-11-15Est. Completion: 2026-01-20
Enrollment target: 20 participants
Locations
University of Alabama at Birmingham, Birmingham, Alabama, United States
Other microbiome trials you might be interested in